| Year |
Citation |
Score |
| 2023 |
Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity. 56: 2188-2205. PMID 37820582 DOI: 10.1016/j.immuni.2023.09.011 |
0.541 |
|
| 2022 |
Atkins MB, Abu-Sbeih H, Ascierto PA, Bishop MR, Chen DS, Dhodapkar M, Emens LA, Ernstoff MS, Ferris RL, Greten TF, Gulley JL, Herbst RS, Humphrey RW, Larkin J, Margolin KA, et al. Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). Journal For Immunotherapy of Cancer. 10. PMID 36175037 DOI: 10.1136/jitc-2022-005413 |
0.372 |
|
| 2020 |
Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, Sum E, Jost C, Fransen MF, Buser RB, Kowanetz M, Rommel K, Matos I, Colombetti S, Belousov A, Karanikas V, ... ... Chen DS, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Science Translational Medicine. 12. PMID 32161104 DOI: 10.1126/Scitranslmed.Aav7431 |
0.52 |
|
| 2020 |
Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 52: 17-35. PMID 31940268 DOI: 10.1016/J.Immuni.2019.12.011 |
0.348 |
|
| 2019 |
Hamid O, Molinero L, Bolen CR, Sosman JA, Muñoz-Couselo E, Kluger HM, McDermott DF, Powderly J, Sarkar I, Ballinger M, Fassò M, O'Hear C, Chen DS, Hegde PS, Hodi FS. Safety, Clinical Activity, and Biological Correlates of Response in Patients With Metastatic Melanoma: Results From a Phase I trial of Atezolizumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31358540 DOI: 10.1158/1078-0432.Ccr-18-3488 |
0.72 |
|
| 2018 |
Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, Kadel EE, Wistuba I, Chaft J, Rizvi NA, Spigel DR, Spira A, Hirsch FR, Cohen V, Smith D, ... ... Chen DS, et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proceedings of the National Academy of Sciences of the United States of America. PMID 30297397 DOI: 10.1073/Pnas.1802166115 |
0.725 |
|
| 2018 |
Chen DS, Hurwitz H. Combinations of Bevacizumab With Cancer Immunotherapy. Cancer Journal (Sudbury, Mass.). 24: 193-204. PMID 30119083 DOI: 10.1097/Ppo.0000000000000327 |
0.644 |
|
| 2018 |
McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, ... ... Chen DS, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine. PMID 29867230 DOI: 10.1038/S41591-018-0053-3 |
0.471 |
|
| 2018 |
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel Iii EE, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, ... ... Chen DS, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. PMID 29443960 DOI: 10.1038/Nature25501 |
0.657 |
|
| 2018 |
von Pawel J, Spigel DR, Ervin T, Losonczy G, Barlesi F, Juhász E, Anderson M, McCall B, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Reck M. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer. The Oncologist. PMID 29438092 DOI: 10.1634/Theoncologist.2017-0690 |
0.343 |
|
| 2018 |
Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, Powles T, Smith D, Hoos A, McKenna C, Beyer U, Rhee I, Fine G, Winslow N, Chen DS, et al. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017751644. PMID 29341833 DOI: 10.1200/Jco.2017.75.1644 |
0.45 |
|
| 2018 |
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Yang Y, Şenbabaoğlu Y, Mellman I, Chen DS, et al. Abstract 2979: A balance of genomic instability, tumor-immune contexture and TGF-β signaling contributing to exclusion of T cells governs response to PD-L1 checkpoint blockade Cancer Research. 78: 2979-2979. DOI: 10.1158/1538-7445.Am2018-2979 |
0.646 |
|
| 2017 |
Adusumilli PS, Cha E, Cornfeld M, Davis T, Diab A, Dubensky TW, Evans E, Grogan JL, Irving BA, Leidner RS, Olwill SA, Soon-Shiong P, Triebel F, Tuck D, Bot A, ... ... Chen DS, et al. New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31(st)Annual Meeting of the Society for Immunotherapy of Cancer, 2016. Journal For Immunotherapy of Cancer. 5: 50. PMID 28649381 DOI: 10.1186/S40425-017-0253-2 |
0.332 |
|
| 2017 |
García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, ... ... Chen D, et al. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. The Oncologist. PMID 28275117 DOI: 10.1634/Theoncologist.2016-0133 |
0.52 |
|
| 2017 |
Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 541: 321-330. PMID 28102259 DOI: 10.1038/Nature21349 |
0.589 |
|
| 2017 |
Rittmeyer A, Smith D, Vansteenkiste J, Fehrenbacher L, Park K, Mazieres J, Artal-Cortes A, Lewanski C, Braiteh F, Yi J, He P, Zou W, Waterkamp D, Ballinger M, Chen D, et al. Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR) Pneumologie. 71: S1-S125. DOI: 10.1200/Jco.2016.34.15_Suppl.9028 |
0.616 |
|
| 2017 |
McDermott D, Huseni M, Rini B, Motzer R, Atkins M, Escudier B, Nickles D, Boyd Z, Sampath S, Doss J, Leng N, Schiff C, Chen DS, Fine G, Powles T, et al. Abstract CT081: Molecular correlates of differential response to Atezolizumab +/- Bevacizumab vs Sunitnib in a Phase II study in untreated metastatic renal cell carcinoma (RCC) patients Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct081 |
0.46 |
|
| 2017 |
Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y, Edward E K, Koeppen H, Astarita J, Cubas R, Jhunjhunwala S, Yang Y, Şenbabaoğlu Y, van der Heijden M, Loriot Y, ... ... Chen D, et al. TGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma Annals of Oncology. 28: xi30. DOI: 10.1093/Annonc/Mdx760.001 |
0.556 |
|
| 2017 |
Schütte W, Barlesi F, Park K, Ciardiello F, Pawel J, Gadgeel S, Hida T, Kowalski D, Cobo Dols M, Cortinovis D, Leach J, Polikoff J, Gandara D, Barrios C, Chen D, et al. Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC Pneumologie. 71: S1-S125. DOI: 10.1055/S-0037-1598278 |
0.501 |
|
| 2017 |
Kowanetz M, Zou W, Shames D, Cummings C, Rizvi N, Spira A, Frampton G, Leveque V, Flynn S, Mocci S, Shankar G, Funke R, Ballinger M, Waterkamp D, Chen D, et al. OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients Journal of Thoracic Oncology. 12: S321-S322. DOI: 10.1016/J.Jtho.2016.11.343 |
0.56 |
|
| 2017 |
Gadgeel S, Ciardiello F, Rittmeyer A, Barlesi F, Cortinovis D, Barrios C, Hida T, Park K, Kowalski D, Cobo Dols M, Leach J, Polikoff J, Matheny C, He P, Kowanetz M, ... Chen D, et al. PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses Journal of Thoracic Oncology. 12: S9-S10. DOI: 10.1016/J.Jtho.2016.11.011 |
0.475 |
|
| 2016 |
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, ... ... Chen DS, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet (London, England). PMID 27979383 DOI: 10.1016/S0140-6736(16)32517-X |
0.647 |
|
| 2016 |
Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, Denker M, Leveque V, Cañamero M, Babitski G, Koeppen H, ... ... Chen DS, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nature Communications. 7: 12624. PMID 27571927 DOI: 10.1038/Ncomms12624 |
0.486 |
|
| 2016 |
Kim JM, Chen DS. Immune-escape to PD-L1/PD-1 blockade: 7 steps to success (or failure). Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27207108 DOI: 10.1093/Annonc/Mdw217 |
0.476 |
|
| 2016 |
Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS, Allison JP, Drake CG, Levitsky H, Lonberg N, van der Burg SH, Fearon DT, Wherry EJ, Lowy I, Vonderheide RH, Hwu P. De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer Immunology Research. 4: 279-88. PMID 27036972 DOI: 10.1158/2326-6066.Cir-16-0045 |
0.518 |
|
| 2016 |
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet (London, England). PMID 26970723 DOI: 10.1016/S0140-6736(16)00587-0 |
0.654 |
|
| 2016 |
Mazieres J, Fehrenbacher L, Rittmeyer A, Spira AI, Park K, Smith DA, Artal-Cortes A, Lewanski CR, Braiteh FS, Yi J, He P, Kowanetz M, Waterkamp D, Ballinger M, Chen DS, et al. Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR. Journal of Clinical Oncology. 34: 9032-9032. DOI: 10.1200/Jco.2016.34.15_Suppl.9032 |
0.595 |
|
| 2016 |
Smith DA, Vansteenkiste JF, Fehrenbacher L, Park K, Mazieres J, Rittmeyer A, Artal-Cortes A, Lewanski CR, Braiteh FS, Yi J, He P, Zou W, Kowanetz M, Waterkamp D, Ballinger M, ... Chen DS, et al. Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR). Journal of Clinical Oncology. 34: 9028-9028. DOI: 10.1200/JCO.2016.34.15_SUPPL.9028 |
0.495 |
|
| 2016 |
Schmid P, Hegde PS, Zou W, Kowanetz M, Mariathasan S, Molinero L, Gadgeel SM, Powles T, Van Der Heijden MS, Fasso M, O'Hear C, Ballinger M, Fine GD, Sandler A, Chen DS, et al. Association of PD-L2 expression in human tumors with atezolizumab activity. Journal of Clinical Oncology. 34: 11506-11506. DOI: 10.1200/Jco.2016.34.15_Suppl.11506 |
0.754 |
|
| 2016 |
Kowanetz M, Koeppen H, Zou W, Mariathasan S, Hellmann M, Kockx M, Chappey C, Kadel E, Smith D, Miley N, Leveque V, Funke R, Sandler A, McCaffery I, Amler L, ... Chen D, et al. Abstract A017: PD-L1 as a predictive biomarker for atezolizumab (MPDL3280A; anti-PDL1) in non-small cell lung cancer (NSCLC) Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A017 |
0.635 |
|
| 2016 |
Barlesi F, Park K, Ciardiello F, von Pawel J, Gadgeel S, Hida T, Kowalski D, Dols M, Cortinovis D, Leach J, Polikoff J, Gandara D, Barrios C, Chen D, He P, et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC Annals of Oncology. 27: vi581. DOI: 10.1093/Annonc/Mdw435.43 |
0.548 |
|
| 2015 |
Gettinger SN, Kowanetz M, Koeppen H, Wistuba II, Kockx M, Kadel EE, Rizvi NA, Spira AI, Hirsch FR, Boyd Z, Denker M, Minn A, Shames DS, Sandler A, Chen DS, et al. Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A. Journal of Clinical Oncology. 33: 3015-3015. DOI: 10.1200/Jco.2015.33.15_Suppl.3015 |
0.595 |
|
| 2015 |
Emens LA, Braiteh FS, Cassier P, Delord J, Eder JP, Fasso M, Xiao Y, Wang Y, Molinero L, Chen DS, Krop I. Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) Cancer Research. 75: 2859-2859. DOI: 10.1158/1538-7445.Am2015-2859 |
0.447 |
|
| 2015 |
Schmid P, Kowanetz M, Koeppen H, Zou W, Wistuba I, Kockx M, Kadel E, Chaft J, Rizvi N, Hirsch F, Smith D, Miley N, Leveque V, Shames D, Sandler A, ... ... Chen D, et al. 3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes European Journal of Cancer. 51: S602. DOI: 10.1016/S0959-8049(16)31661-6 |
0.725 |
|
| 2015 |
Vansteenkiste J, Fehrenbacher L, Spira A, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Yi J, He P, Kowanetz M, Waterkamp D, Ballinger M, Chen D, et al. 14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR) European Journal of Cancer. 51: S716-S717. DOI: 10.1016/S0959-8049(15)30072-1 |
0.572 |
|
| 2014 |
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, ... ... Chen DS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515: 563-7. PMID 25428504 DOI: 10.1038/Nature14011 |
0.674 |
|
| 2014 |
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 515: 558-62. PMID 25428503 DOI: 10.1038/Nature13904 |
0.543 |
|
| 2014 |
Xiao Y, Rabe C, Kowanetz M, Powles T, Vogelzang NJ, Petrylak DP, Loriot Y, Denker M, Nakamura R, Wu QJ, Sumiyoshi T, Boyd Z, Teng S, Shen X, Fine GD, ... Chen DS, et al. Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer (UBC) F1000research. 5. DOI: 10.7490/F1000Research.1097333.1 |
0.382 |
|
| 2014 |
Kowanetz M, Rabe C, Xiao Y, Wu QJ, Koeppen H, Leddy C, Patel RD, Powderly J, Kohrt H, Gettinger S, Soria J, Herbst RS, Desai R, Denker M, Ruppel J, ... ... Chen DS, et al. Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A Journal For Immunotherapy of Cancer. 2. DOI: 10.7490/F1000Research.1097332.1 |
0.479 |
|
| 2014 |
Powles T, Vogelzang NJ, Fine GD, Eder JP, Braiteh FS, Loriot Y, Cruz Zambrano C, Bellmunt J, Burris HA, Teng SM, Shen X, Koeppen H, Hegde PS, Chen DS, Petrylak DP. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). Journal of Clinical Oncology. 32: 5011-5011. DOI: 10.1200/Jco.2014.32.15_Suppl.5011 |
0.514 |
|
| 2014 |
Xiao Y, Rabe C, Kowanetz M, Powles T, Vogelzang NJ, Petrylak DP, Loriot Y, Denker M, Nakamura R, Wu QJ, Sumiyoshi T, Boyd Z, Teng SM, Shen X, Fine G, ... Chen DS, et al. Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P131 |
0.507 |
|
| 2014 |
Sagiv-Barfi I, Rajapaksa A, Czerwinski D, Chang S, Hebb J, Chester C, Waller E, Fine G, Chen D, Kowanetz M, Irving B, Levy R, Kohrt H. Abstract 2941: Local tumor irradiation combined with α-PDL-1 immune checkpoint inhibition results in local and systemic anti-tumor responses: Successful translation of a mouse model to a human case series Cancer Research. 74: 2941-2941. DOI: 10.1158/1538-7445.Am2014-2941 |
0.432 |
|
| 2013 |
Johnson L, Huseni M, Smyczek T, Lima A, Yeung S, Cheng JH, Molina R, Kan D, De Mazière A, Klumperman J, Kasman I, Zhang Y, Dennis MS, Eastham-Anderson J, Jubb AM, ... ... Chen DS, et al. Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. The Journal of Clinical Investigation. 123: 3997-4009. PMID 23945239 DOI: 10.1172/Jci67892 |
0.374 |
|
| 2013 |
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 39: 1-10. PMID 23890059 DOI: 10.1016/J.Immuni.2013.07.012 |
0.602 |
|
| 2013 |
Brauer MJ, Zhuang G, Schmidt M, Yao J, Wu X, Kaminker JS, Jurinka SS, Kolumam G, Chung AS, Jubb A, Modrusan Z, Ozawa T, James CD, Phillips H, Haley B, ... ... Chen D, et al. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3681-92. PMID 23685835 DOI: 10.1158/1078-0432.Ccr-12-3635 |
0.318 |
|
| 2013 |
Hegde PS, Jubb AM, Chen D, Li NF, Meng YG, Bernaards C, Elliott R, Scherer SJ, Chen DS. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 929-37. PMID 23169435 DOI: 10.1158/1078-0432.Ccr-12-2535 |
0.327 |
|
| 2013 |
Hamid O, Sosman JA, Lawrence DP, Sullivan RJ, Ibrahim N, Kluger HM, Boasberg PD, Flaherty K, Hwu P, Ballinger M, Mokatrin A, Kowanetz M, Chen DS, Hodi FS. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). Journal of Clinical Oncology. 31: 9010-9010. DOI: 10.1200/Jco.2013.31.15_Suppl.9010 |
0.459 |
|
| 2013 |
Spigel DR, Gettinger SN, Horn L, Herbst RS, Gandhi L, Gordon MS, Cruz C, Conkling P, Cassier PA, Antonia SJ, Burris HA, Fine GD, Mokatrin A, Kowanetz M, Shen X, ... Chen DS, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 31: 8008-8008. DOI: 10.1200/Jco.2013.31.15_Suppl.8008 |
0.506 |
|
| 2013 |
Tabernero J, Powderly JD, Hamid O, Gordon MS, Fisher GA, Braiteh FS, Garbo LE, Fine GD, Kowanetz M, McCall B, Shen X, Chen DS, Kohrt HE. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors. Journal of Clinical Oncology. 31: 3622-3622. DOI: 10.1200/Jco.2013.31.15_Suppl.3622 |
0.511 |
|
| 2013 |
Powderly JD, Koeppen H, Hodi FS, Sosman JA, Gettinger SN, Desai R, Tabernero J, Soria J, Hamid O, Fine GD, Xiao Y, Mokatrin A, Wu J, Anderson M, Irving BA, ... Chen DS, et al. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study. Journal of Clinical Oncology. 31: 3001-3001. DOI: 10.1200/Jco.2013.31.15_Suppl.3001 |
0.542 |
|
| 2013 |
Herbst RS, Gordon MS, Fine GD, Sosman JA, Soria J, Hamid O, Powderly JD, Burris HA, Mokatrin A, Kowanetz M, Leabman M, Anderson M, Chen DS, Hodi FS. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. Journal of Clinical Oncology. 31: 3000-3000. DOI: 10.1200/Jco.2013.31.15_Suppl.3000 |
0.501 |
|
| 2013 |
Kohrt H, Kowanetz M, Gettinger S, Powderly J, Koeppen H, Sosman JA, Cruz C, Xiao Y, Mokatrin A, Fine G, Chen DS, Hodi FS. Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1 Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-O12 |
0.541 |
|
| 2013 |
Gordon MS, Hamid O, Powderly J, Anderson M, Fine G, Mokatrin A, Kowanetz M, Maya L, Irving BA, Chen DS, Hodi FS. Abstract LB-288: A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-288 |
0.47 |
|
| 2013 |
Chen D. Development of MPDL3280A, an Anti-PD-L1 Antibody Engineered for Enhanced Efficacy and Safety Annals of Oncology. 24: i7. DOI: 10.1093/Annonc/Mdt042.3 |
0.423 |
|
| 2012 |
Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA, Swetter SM, Knox SJ. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Translational Oncology. 5: 404-7. PMID 23323154 DOI: 10.1593/Tlo.12280 |
0.39 |
|
| 2012 |
Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6580-7. PMID 23087408 DOI: 10.1158/1078-0432.Ccr-12-1362 |
0.493 |
|
| 2012 |
Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE, O'Day SJ. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 34-41. PMID 22124101 DOI: 10.1200/Jco.2011.34.6270 |
0.329 |
|
| 2012 |
Goldman JW, Gordon MS, Munster PN, Bergsland EK, Moore AP, Bai S, Hegde P, Fredrickson JO, Chang I, Chandler GS, Funke RP, Rhee IP, Chen DS, Rosen LS. Phase Ib study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab (bev) with or without paclitaxel. Journal of Clinical Oncology. 30: e13000-e13000. DOI: 10.1200/Jco.2012.30.15_Suppl.E13000 |
0.419 |
|
| 2012 |
Peale F, Sanders L, Yu R, Chan S, Chen d, Raja R, Patel R, Malekafzali A, Hegde P, Ye W, Schmidt M. Abstract LB-312: Egfl7 is expressed in a broad range of human tumors with apparent restriction to the endothelium Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-312 |
0.32 |
|
| 2012 |
Hurvitz SA, Hegde P, Bosserman L, Allison MA, Thirlwell M, Yeh R, Fu L, Schmidt M, Leyland-Jones B, Quan E, Molthrop D, Barstis J, Park D, Keane M, Upadhyaya G, ... ... Chen DS, et al. Abstract 1385: Molecular changes in breast tumors following bevacizumab-based treatment: Final analysis of a randomized neoadjuvant study of bevacizumab or placebo, followed by chemotherapy with or without bevacizumab, in patients with stage II or III breast cancer Cancer Research. 72: 1385-1385. DOI: 10.1158/1538-7445.Am2012-1385 |
0.326 |
|
| 2011 |
Rosen LS, Gordon MS, Bai S, Hegde P, Fredrickson J, Chen DS, Chang I, Funke RP, Chandler GS, Naumovski L, Munster PN. A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2614. PMID 28022950 DOI: 10.1200/Jco.2011.29.15_Suppl.2614 |
0.39 |
|
| 2011 |
Naumovski L, Gordon MS, Munster PN, Hegde P, Fredrickson J, Bai S, Funke RP, Chang I, Chandler GS, Chen DS, Rosen LS. A phase Ib dose-escalation study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2514. PMID 28022353 DOI: 10.1200/Jco.2011.29.15_Suppl.2514 |
0.384 |
|
| 2011 |
Fredrickson J, Chang I, Friesenhahn M, Ashton E, Munster PN, Gordon MS, Chen DS, Naumovski L, de Crespigny A, Rosen LS. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a pharmacodynamic (PD) biomarker in phase I trials of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2539. PMID 28022334 DOI: 10.1200/Jco.2011.29.15_Suppl.2539 |
0.365 |
|
| 2011 |
Xin Y, Gordon MS, Jin D, Wakshull E, Chen DS, Rosen LS, Munster PN, Naumovski L, Bai S. Population pharmacokinetic (PK) analysis supports fixed dosing for the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2586. PMID 28022261 DOI: 10.1200/Jco.2011.29.15_Suppl.2586 |
0.325 |
|
| 2011 |
Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 372-81. PMID 21224365 DOI: 10.1158/1078-0432.Ccr-10-1791 |
0.335 |
|
| 2011 |
Jubb AM, Strickland LA, Chen DS, Schmidt M, Koeppen H. Abstract 5130: Neuropilin-1 expression in breast, colorectal and lung cancer Cancer Research. 71: 5130-5130. DOI: 10.1158/1538-7445.Am2011-5130 |
0.359 |
|
| 2010 |
Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh RF, Pirzkall A, Fine BM, Amler LC, Chen DS, Lackner MR. Molecular biomarker analyses using circulating tumor cells. Plos One. 5. PMID 20838621 DOI: 10.1371/Journal.Pone.0012517 |
0.367 |
|
| 2010 |
Hegde P, Xing B, O'Day S, Kim KB, Schmidt M, Scherer SJ, Nguyen H, Peterson AC, Cheverton P, Chen DS. Biomarkers of treatment benefit in a randomized phase II study of bevacizumab in combination with carboplatin and paclitaxel in metastatic melanoma patients (BEAM). Journal of Clinical Oncology. 28: 10563-10563. DOI: 10.1200/Jco.2010.28.15_Suppl.10563 |
0.304 |
|
| 2010 |
Bernaards C, Hegde P, Chen D, Holmgren E, Zheng M, Jubb AM, Koeppen H, Scherer SJ, Chen DS. Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies. Journal of Clinical Oncology. 28: 10519-10519. DOI: 10.1200/Jco.2010.28.15_Suppl.10519 |
0.365 |
|
| 2010 |
Atwal SK, Savage H, Spoerke J, Mohan S, Pandita A, Chen D, Lackner M, Punnoose E. Abstract 5768: Predictive diagnostics from circulating tumor cells Cancer Research. 70: 5768-5768. DOI: 10.1158/1538-7445.Am10-5768 |
0.34 |
|
| 2006 |
Huse M, Lillemeier BF, Kuhns MS, Chen DS, Davis MM. T cells use two directionally distinct pathways for cytokine secretion. Nature Immunology. 7: 247-55. PMID 16444260 DOI: 10.1038/Ni1304 |
0.667 |
|
| 2006 |
Chen DS, Davis MM. Molecular and functional analysis using live cell microarrays Current Opinion in Chemical Biology. 10: 28-34. PMID 16413817 DOI: 10.1016/J.Cbpa.2006.01.001 |
0.41 |
|
| 2005 |
Chen DS, Soen Y, Stuge TB, Lee PP, Weber JS, Brown PO, Davis MM. Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. Plos Medicine. 2: e265. PMID 16162034 DOI: 10.1371/Journal.Pmed.0020265 |
0.517 |
|
| 2005 |
Chen DS, Davis MM. Cellular immunotherapy: Antigen recognition is just the beginning Springer Seminars in Immunopathology. 27: 119-127. PMID 15834723 DOI: 10.1007/S00281-005-0200-Z |
0.511 |
|
| 2004 |
Soen Y, Chen DS, Stuge TB, Weber JS, Lee PP, Brown PO, Davis MM. A novel cellular microarray identifies functional deficiencies in tumor-specific T cell responses. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2510. PMID 28015026 DOI: 10.1200/Jco.2004.22.14_Suppl.2510 |
0.511 |
|
| 2004 |
Chen DS, Soen Y, Davis MM, Brown PO. Functional and molecular profiling of heterogeneous tumor samples using a novel cellular microarray Journal of Clinical Oncology. 22: 9507-9507. DOI: 10.1200/Jco.2004.22.90140.9507 |
0.454 |
|
| 2004 |
Kraft D, Soen Y, Chen D, Weissman I, Brown P, Davis M. Development of an MHC-peptide array for the detection and isolation of antigen-specific T-cells: applications in bone marrow transplantation for evaluation of T-cell reconstitution, and detection of host reactive and tumor-reactive T-cells Biology of Blood and Marrow Transplantation. 10: 24. DOI: 10.1016/J.Bbmt.2003.12.097 |
0.465 |
|
| 2003 |
Soen Y, Chen DS, Kraft DL, Davis MM, Brown PO. Detection and characterization of cellular immune responses using peptide-MHC microarrays. Plos Biology. 1: E65. PMID 14691537 DOI: 10.1371/Journal.Pbio.0000065 |
0.482 |
|
| 1997 |
Kraeft SK, Chen DS, Li HP, Chen LB, Lai MM. Mouse hepatitis virus infection induces an early, transient calcium influx in mouse astrocytoma cells. Experimental Cell Research. 237: 55-62. PMID 9417866 DOI: 10.1006/Excr.1997.3768 |
0.476 |
|
| 1997 |
Chen DS, Asanaka M, Chen FS, Shively JE, Lai MM. Human carcinoembryonic antigen and biliary glycoprotein can serve as mouse hepatitis virus receptors. Journal of Virology. 71: 1688-91. PMID 8995701 DOI: 10.1128/Jvi.71.2.1688-1691.1997 |
0.48 |
|
| 1995 |
Chen DS, Asanaka M, Yokomori K, Wang F, Hwang SB, Li HP, Lai MM. A pregnancy-specific glycoprotein is expressed in the brain and serves as a receptor for mouse hepatitis virus. Proceedings of the National Academy of Sciences of the United States of America. 92: 12095-9. PMID 8618851 DOI: 10.1073/Pnas.92.26.12095 |
0.473 |
|
| 1994 |
Lee CZ, Chen PJ, Lai MM, Chen DS. Isoprenylation of large hepatitis delta antigen is necessary but not sufficient for hepatitis delta virus assembly. Virology. 199: 169-75. PMID 8116240 DOI: 10.1006/viro.1994.1109 |
0.385 |
|
| 0 |
Chen DS. . PMID 29443960 |
0.423 |
|
| 0 |
Chen DS. . PMID 28102259 |
0.341 |
|
| 0 |
Chen DS. . PMID 23890059 |
0.35 |
|
| Show low-probability matches. |
